Hearing Aid BTE RIC denied as experimental or investigational by Humana?

Humana's specific coverage criteria for hearing aid bte ric are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denies Behind-the-Ear / Receiver-in-Canal Hearing Aids as Experimental

Conventional BTE and RIC hearing aids are FDA-cleared, widely used devices with decades of clinical evidence — but Humana may apply an "experimental" or "investigational" label to specific advanced features (such as certain wireless connectivity protocols, artificial-intelligence-driven sound processing, or novel fitting algorithms) that have been recently introduced and lack extensive published outcomes data. The denial may target the device as a whole or only the specific feature set being claimed. Understanding exactly which aspect Humana considers experimental is essential to crafting the appeal.

## Why This Denial Is Appealable

For a device that is FDA-cleared, an "experimental" denial is very difficult for Humana to sustain at external review. FDA clearance reflects a determination that the device is substantially equivalent to a legally marketed predicate — that is a federal safety and efficacy determination. Denying a cleared device as experimental requires Humana to show that its own evidence standard is a recognized and appropriate one. Under ACA §2719, external IRO reviewers evaluate whether a denial is consistent with generally accepted standards of medical practice — FDA clearance is strong evidence that it is. ERISA §503 applies to employer plans. The external-review window is approximately four months; expedited review is available for urgent situations.

## The Appeal Process

1. Obtain Humana's experimental/investigational criteria. Humana must specify which evidence standard it is applying and which aspect of the device fails to meet it. 2. Pull the FDA 510(k) clearance record for the specific hearing-aid model — available on the FDA's public database — and attach it as Exhibit A. 3. File a Level 1 internal appeal with the FDA clearance documentation and a professional-society statement (e.g., from the American Academy of Audiology or the American Academy of Otolaryngology–Head and Neck Surgery) affirming that BTE/RIC amplification is the accepted standard of care for the patient's type and degree of hearing loss. 4. Request external review if the internal appeal is denied — IRO reviewers apply an objective clinical-standard test that FDA-cleared devices typically satisfy.

## Documentation to Gather

• FDA clearance record: The 510(k) summary or De Novo authorization for the specific hearing-aid model, showing the FDA-recognized indications and the predicate device.
• Audiological evaluation: Current audiogram and audiologist's recommendation explaining why this specific device type is clinically indicated.
• Professional-society support: Position statement or clinical practice guideline from the American Academy of Audiology, AAO-HNS, or other relevant body affirming BTE/RIC amplification as accepted practice for this degree and configuration of hearing loss.
• Peer-reviewed literature: If Humana's denial cites lack of evidence, include published studies supporting the device category — obtainable from PubMed without cost.
• Medical-necessity letter: Audiologist or ENT letter connecting the patient's diagnosis and audiometric findings to the FDA-cleared indication and the professional-society standard.

## Criteria-Mapping Structure

| Humana Experimental Criterion | Patient-Specific Rebuttal | |---|---| | [Quote Humana's experimental standard verbatim] | [FDA clearance reference, professional-society citation, or clinical evidence responding to each element] |

The goal is to demonstrate that every element of Humana's experimental-evidence standard is satisfied by publicly available, objective evidence — leaving no criterion unaddressed.